NCT04469673View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

May 3, 2020

Study Completion Date

June 28, 2020

Conditions
Hyperlipemia
Interventions
BIOLOGICAL

Biological：JS002

Administered by subcutaneous injection

BIOLOGICAL

Placebo

Administered by subcutaneous injection

Trial Locations (1)

Unknown

Fuwai Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT04469673 - A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia.. | Biotech Hunter | Biotech Hunter